Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2012-11-05 Earnings Release
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2012, reporting preliminary operating and financial results for the quarter ended September 30, 2012. It includes a press release as an exhibit announcing these results. The text explicitly states this is a current report and the press release is furnished as Exhibit 99.1. The document is short (2961 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this filing is best classified as an Earnings Release (ER).
2012-11-05 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements. The text describes the entry into a Settlement Agreement and Mutual Release, termination of a License Agreement, and an Amended and Restated License Agreement. It references that the full agreements will be filed as exhibits to the Annual Report on Form 10-K, indicating this document is an announcement of these agreements rather than the agreements themselves. The content focuses on material definitive agreements and their termination, which is typical for a Form 8-K. This fits best under the category of Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain full financial statements or detailed financial data. The document length and content confirm it is not a brief announcement but a detailed regulatory filing. Therefore, the classification is RNS with high confidence.
2012-11-05 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes management's determination of errors in previously issued financial statements and the intention to restate those financial statements, including amended 10-K and 10-Q filings. It also discusses the impact on internal controls and audit reports. This is not the annual report itself, nor is it a full audit report or interim report, but rather a regulatory filing to disclose material information about restatements and internal control weaknesses. The document is about disclosure of financial restatement and related audit issues, typical of a Regulatory Filing (RNS). The document length (6985 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2012-11-05 English
4 Filing
Director's Dealing
2012-11-02 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions the filing of a press release about a milestone payment related to a clinical trial. There are no financial statements or detailed financial data included, only a reference to the press release as an exhibit. The document length is short (2615 characters), and it primarily serves as an announcement of an event rather than a detailed financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-10-22 English
4 Filing
Director's Dealing
2012-09-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.